RECRUITING

Pre-myeloid Cancer and Bone Marrow Failure Clinic Study

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This clinical trial tests next generation sequencing (NGS) for the detection of precursor features of pre-myeloid cancers and bone marrow failure syndromes. NGS is a procedure that looks at relevant cancer associated genes and what they do. Finding genetic markers for pre-malignant conditions may help identify patients who are at risk of pre-myeloid cancers and bone marrow failure syndromes and lead to earlier intervention.

Official Title

Pre-myeloid Cancer and Bone Marrow Failure Clinic Study

Quick Facts

Study Start:2017-01-16
Study Completion:2035-09-15
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT02958462

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients with idiopathic cytopenias of unclear significance (ICUS)
  2. * Patients with clonal hematopoiesis of indeterminate significance (clonal hematopoiesis of indeterminate potential \[CHIP\]), including the recently described CHIP syndrome called VEXAS (vacuoles, E1 ubiquitin ligase, X chromosomal, autoimmune and somatic)
  3. * Patients with clonal cytopenias of undetermined significance (CCUS)
  4. * Marrow failure syndromes with myeloid malignancy predisposition - telomere dysfunction, chromosomal breakage disorders
  5. * Germ line inherited syndromes with risk for malignant transformation - GATA2, CEBPA, ETV-6, RUNX1, JAK2, PF6, etc.
  6. * Low risk MDS (idiopathic dysplasia of unclear significance)
  7. * Family member of a patient with one of the above conditions
  8. * Patient at high risk or suspected of developing one of the above conditions
  1. * Patients under 18 years of age

Contacts and Locations

Study Contact

Brittany Burnap
CONTACT
507-293-1764
cimpmlresearch@mayo.edu
Clinical Trials Referral Office
CONTACT
855-776-0015
mayocliniccancerstudies@mayo.edu

Principal Investigator

Mrinal S. Patnaik, MBBS
PRINCIPAL_INVESTIGATOR
Mayo Clinic

Study Locations (Sites)

Mayo Clinic in Arizona
Scottsdale, Arizona, 85259
United States
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980
United States
Mayo Clinic in Rochester
Rochester, Minnesota, 55905
United States

Collaborators and Investigators

Sponsor: Mayo Clinic

  • Mrinal S. Patnaik, MBBS, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2017-01-16
Study Completion Date2035-09-15

Study Record Updates

Study Start Date2017-01-16
Study Completion Date2035-09-15

Terms related to this study

Additional Relevant MeSH Terms

  • Myeloid Malignancy
  • Inherited Bone Marrow Failure Syndrome
  • Clonal Expansion
  • Cytopenia
  • Bone Marrow Failure Syndrome
  • Clonal Cytopenia of Undetermined Significance
  • Clonal Hematopoiesis of Indeterminate Potential
  • Hematologic Neoplasms
  • Hematopoietic and Lymphatic System Neoplasm
  • Hereditary Neoplastic Syndrome
  • Idiopathic Cytopenia of Undetermined Significance
  • Idiopathic Dysplasia of Uncertain Significance
  • Low Risk Myelodysplastic Syndrome